Effect of N-acetyl cysteine supplementation versus placebo on clinical outcomes in women with chronic pelvic pain syndrome

Effect of N-acetyl cysteine supplementation versus placebo on clinical outcomes in women with chronic pelvic pain syndrome: a double-blind randomized clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20120215009014N376

Enrollment

Registered

2021-01-22

Start date

2021-04-21

Completion date

Unknown

Last updated

2021-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic pelvic pain syndrome. Pelvic and perineal pain

Interventions

Intervention 1: Intervention group: Amitriptyline 25 mg daily plus N-acetyl cysteine tablets (manufactured by Osweh Pharmaceutical Co., Tehran, Iran) 600 mg every 12 hours for 2 months. Intervention 2

Eligibility

Sex/Gender

Female

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Age of 18 to 50 years, Women with chronic pelvic pain syndrome for at least 6 months,

Exclusion criteria

Exclusion criteria: Presence of pathologic or infamous reason for chronic pelvic pain, Mild symptoms (the score less than 15 based on NIH-CPSI questionnaire), Chronic liver or renal disease, Kidney stone or urogenital tract infection, History of surgery of urogenital tract, Contraindication of N-acetyl cysteine

Design outcomes

Primary

Measure	Time frame
Clinical symptoms. Timepoint: Before the intervention and 4 and 8 weeks after that. Method of measurement: Using the National Institutes of Health - Chronic Prostatitis Symptom Index (NIH-CPSI) standard questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSomayeh Rahymy

Hamedan University of Medical Sciences

rhymy2958@gmail.com+98 81 3838 0572

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026